benzyl ethyl(2-hydroxyethyl)carbamate | 67249-24-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl ethyl(2-hydroxyethyl)carbamate
• 英文别名: N-benzyloxycarbonyl-N-ethyl-2-aminoethanol；benzyl N-ethyl N-(2-hydroxyethyl) carbamate；benzyl N-ethyl-N-(2-hydroxyethyl)carbamate
• CAS: 67249-24-5
• 化学式: C₁₂H₁₇NO₃
• 分子量: 223.272
• InChiKey: QSZNUISNXJMTKA-UHFFFAOYSA-N

物化性质

• 沸点：
  354.9±31.0 °C(Predicted)
• 密度：
  1.136±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  benzyl ethyl(2-hydroxyethyl)carbamate 在 咪唑 、 碘 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 以29%的产率得到benzyl ethyl(2-iodoethyl)carbamate
  参考文献：
  名称：

  摘要：

  The metabolism of the potent antiarrythmic drug amiodarone (AMI 1) has yet not been fully investigated. Recently, in vitro experiments revealed that in rabbit-liver microsomes, AMI (1) and its main metabolite MDEA (2) were biotransformed to the hydroxylated derivatives T-OH-AMI (3) and 3'-OH-MDEA (4). respectively. To establish the chemical structure of 3 and 4, we developed a total synthesis of these two metabolites of AMI (1). H-1- and C-13-NMR Signal assignment from HSQC and HMBC 2D NMR data of synthesized 4 showed that the proposed structure of metabolite 4 is correct. Even the structure of 3 was found to be correct by comparing its HPLC/MS-MS/MS with the data described earlier.

  DOI：

  10.1002/1522-2675(200209)85:9<2990::aid-hlca2990>3.0.co;2-r
• 作为产物：
  描述：

  氯甲酸苯酯 、 N-乙基乙醇胺 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以97%的产率得到benzyl ethyl(2-hydroxyethyl)carbamate
  参考文献：
  名称：

  CHEMICAL COMPOUNDS

  摘要：

  本发明涉及式(I)的化合物及其盐、药物组合物、使用方法和制备方法。这些化合物抑制Bcl-2和/或Bcl-XL活性，可用于癌症的治疗。

  公开号：

  US20120035134A1

文献信息

• [EN] SORDARIN DERIVATIVES FOR PREVENTING OR TREATING INFECTIOUS DISEASES CAUSED BY PATHOGENIC MICROORGANISMS<br/>[FR] DÉRIVÉS DE SORDARINE POUR PRÉVENIR OU TRAITER DES MALADIES INFECTIEUSES CAUSÉES PAR DES MICRO-ORGANISMES PATHOGÈNES
  申请人：ASTELLAS PHARMA INC

  公开号：WO2009131246A1

  公开（公告）日：2009-10-29

  This invention relates to a new sordarin derivative or a pharmaceutically acceptable salt thereof, which has antimicrobial activities (especially, antifungal activities), to process for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for prophylactic and/or therapeutic treatment of infectious diseases in a human being or an animal.

  这项发明涉及一种新的索达林衍生物或其药用可接受的盐，该衍生物具有抗菌活性（特别是抗真菌活性），其制备方法，包含该衍生物的药物组合物，以及用于预防或治疗人类或动物传染性疾病的方法。
• [EN] AMIDOETHYL AZOLE OREXIN RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DES RÉCEPTEURS D'OREXINE DE TYPE AMIDOÉTHYLAZOLE
  申请人：MERCK SHARP & DOHME

  公开号：WO2016101118A1

  公开（公告）日：2016-06-30

  An amidoethyl azole compounds are provided as antagonists of orexin receptors. The compounds may be used for treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved.

  提供了一种酰胺乙基唑类化合物作为促进睡眠的受体拮抗剂。这些化合物可用于治疗或预防涉及促进睡眠受体的神经和精神障碍和疾病。
• RILUZOLE PRODRUGS AND THEIR USE
  申请人：Biohaven Pharmaceutical Holding Company Ltd.

  公开号：US20180036290A1

  公开（公告）日：2018-02-08

  Pharmaceutical compositions of the invention include substituted riluzole prodrugs useful for the treatment of cancers including melanoma, breast cancer, brain cancer, and prostate cancer through the release of riluzole. Prodrugs of riluzole have enhanced stability to hepatic metabolism and are delivered into systemic circulation by oral administration, and then cleaved to release riluzole in the plasma via either an enzymatic or general biophysical release process.

  本发明的制药组合物包括替代利鲁唑前药，通过释放利鲁唑治疗包括黑色素瘤、乳腺癌、脑癌和前列腺癌等癌症。利鲁唑的前药具有增强的肝代谢稳定性，并通过口服途径输送到全身循环中，然后通过酶促或一般的生物物理释放过程在血浆中裂解释放利鲁唑。
• [EN] N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2012017251A1

  公开（公告）日：2012-02-09

  The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-XL activities and may be used for the treatment of cancer.

  本发明涉及式（I）的化合物及其盐，制药组合物，使用方法和制备方法。这些化合物抑制Bcl-2和/或Bcl-XL的活性，可用于治疗癌症。
• N-ACYLSULFONAMIDE APOPTOSIS PROMOTERS
  申请人：Diebold Robert Bruce

  公开号：US20130310344A1

  公开（公告）日：2013-11-21

  The present invention relates to compounds of Formula (I): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit Bcl-2 and/or Bcl-X L activities and may be used for the treatment of cancer.

  本发明涉及式（I）的化合物及其盐、药物组合物、使用方法和制备方法。这些化合物可以抑制Bcl-2和/或Bcl-XL活性，并可用于治疗癌症。